Has Stanley Waintraub, MD received payments from drug or device companies?

Yes. Drug and device makers reported $947 in general payments to Stanley Waintraub, MD across 43 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stanley Waintraub, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stanley Waintraub, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stanley Waintraub, MD

Medical Oncology · Hackensack, NJNPI 1609835586

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $828 of the $947 with a category attached, or 87.4%. 13 manufacturers reported payments, led by Daiichi Sankyo Inc. at 32.1% of the total. 2025 is the largest year on record at $345, 6.0 times the $58 reported in 2019. That places this record below the midpoint for medical oncology clinicians in NJ, where the typical reported total is $1,937.

$947in general payments, 2019–2025

Across 43 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$305
Gilead$274
Novartis$122
AstraZeneca$42
Merck$38
Genentech USA, Inc.$36
plus $131 from 7 others

$468,110in research payments, 2019–2025

Across 45 payments — averaging $10,402 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$268K
Genentech, Inc.$200K

What the payments were for

Food & beverage$82887%
Education$12013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	6	$305
Gilead	16	$274
Novartis	6	$122
AstraZeneca	3	$42
Merck	2	$38
Genentech USA, Inc.	2	$36
E.r. Squibb & Sons, L.L.C.	2	$30
Puma Biotechnology, Inc.	1	$21
Biocon Biologics Inc	1	$20
Tersera Therapeutics LLC	1	$19
Jazz Pharmaceuticals Inc.	1	$17
Regeneron Healthcare Solutions, Inc.	1	$12
Johnson & Johnson	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Enhertu$143

How this compares

$947 in reported general payments places this provider in the 40th percentile of 112 medical oncology providers in New Jersey.

See all medical oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$440,441

Medicare patients

784

Services billed

30,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
IbrancePalbociclib	70	$1,055,147
VerzenioAbemaciclib	48	$621,973
ArimidexAnastrozole	25	$59,698
Exemestane	231	$33,878
EliquisApixaban	31	$24,508
Anastrozole	716	$15,303
Letrozole	124	$2,750
Erlotinib Hcl	13	$2,054
Raloxifene Hcl	15	$927
Prochlorperazine Maleate	26	$290
Tamoxifen Citrate	11	$271
Gabapentin	11	$258
Levothyroxine Sodium	20	$170
Warfarin Sodium	21	$131
Ondansetron Hcl	12	$78

Paid to pharmacies, not to this prescriber.

Other medical oncology in Hackensack

James McCloskeyHackensack$2.8M
Jamie KoprivnikarHackensack$1.7M
Andrew PecoraHackensack$1.2M
David VesoleHackensack$726K
Lori LeslieHackensack$665K
Noa BiranHackensack$263K
Robert AlterHackensack$232K
Harry HarperHackensack$226K
Tatyana FeldmanHackensack$193K
David SiegelHackensack$171K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →